Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma 1Head and Neck Carcinoma of Unknown Primary 1

Interventions

pembrolizumab 10Cisplatin 8Radiotherapy 6Magnetic Resonance Spectroscopy 6Carboplatin 6Specimen Handling 5Paclitaxel 5Brachytherapy 5Fluorodeoxyglucose F18 4dostarlimab 3atezolizumab 3Trastuzumab 3Radiation 3Platinum 3Nivolumab 3Human Papillomavirus DNA Tests 3Docetaxel 3Colposcopy 31,2-diaminocyclohexaneplatinum II citrate 3zimberelimab 2tislelizumab 2spartalizumab 2olaparib 2human papillomavirus vaccine, L1 type 16, 18 2durvalumab 2Vaccines 2Surveys and Questionnaires 2Standard of Care 2Robotic Surgical Procedures 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Uterine Cervical Neoplasms × ASTX-660 × Clear all
NCT02503423 2026-03-20

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Taiho Oncology, Inc.

Phase 1/2 Active not recruiting
253 enrolled
GynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡